MedDataX Logo

Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina

NCT ID: NCT00185263

Last Updated: 2008-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-03-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality of life, and cardiovascular outcomes. To doses are to be studied, 2.87x10(8) and 2.87x10(9) viral particles, to evaluate the dose-response of Ad5FGF-4. Short-term and long-term safety of Ad5FGF-4 will also be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)

NCT00346437

Angina Pectoris
COMPLETED PHASE2/PHASE3

Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization

NCT00438867

Angina Pectoris
UNKNOWN PHASE3

Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia

NCT02928094

Angina, Stable
UNKNOWN PHASE3

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

NCT01763996

Coronary Artery Disease
COMPLETED PHASE4

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

NCT04306237

Refractory Angina
WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stable Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Ad5FGF-4

Group Type EXPERIMENTAL

AdF5FGF-4 vs. Placebo

Intervention Type GENETIC

Intracoronary infusion

2

Ad5FGF-4

Group Type EXPERIMENTAL

AdF5FGF-4 vs. Placebo

Intervention Type GENETIC

Intracoronary infusion

3

Placebo

Group Type PLACEBO_COMPARATOR

AdF5FGF-4 vs. Placebo

Intervention Type GENETIC

Intracoronary infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AdF5FGF-4 vs. Placebo

Intracoronary infusion

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CCS class II - IV, technically unsuitable for revascularization by CABG or PTCA able to exercise between 3 and 10 minutes on treadmill

Exclusion Criteria

* Unstable angina, CCS class 1 angina optimal candidates for revascularization
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardium Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cardium Therapeutics

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Foster, MD

Role: STUDY_DIRECTOR

Cardium Therapeutics, 12255 El Camino Real, Suite 250, San Diego, CA 92130, USA, +1-858-436-1000

References

Explore related publications, articles, or registry entries linked to this study.

Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, Engler RL. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. doi: 10.1016/j.jacc.2007.06.010. Epub 2007 Aug 24.

Reference Type DERIVED
PMID: 17825712 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

305602

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease
NCT01002430 COMPLETED PHASE1
To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter
NCT00090714 UNKNOWN PHASE2
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
NCT02575833 COMPLETED PHASE2
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
NCT07091929 COMPLETED PHASE1
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
NCT04848220 TERMINATED PHASE2
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
NCT02601560 COMPLETED PHASE2
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
NCT00269906 COMPLETED PHASE3
Gene Therapy for the Treatment of Chronic Stable Angina
NCT01002495 WITHDRAWN PHASE1/PHASE2
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
NCT04610892 COMPLETED PHASE2
Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)
NCT04826172 COMPLETED PHASE2
GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
NCT02377336 WITHDRAWN PHASE2
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
NCT01294709 COMPLETED PHASE1
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
NCT00751608 WITHDRAWN PHASE2
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
NCT01549977 TERMINATED PHASE2
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
NCT04669262 COMPLETED PHASE1
Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial
NCT00620217 COMPLETED PHASE2
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
NCT01609140 COMPLETED PHASE2
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
NCT02284048 UNKNOWN PHASE4
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
NCT03004638 COMPLETED PHASE2
Yinxingmihuan Oral Solution in Treatment of Chest Pain After PCI
NCT06224582 COMPLETED NA
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
NCT04999293 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease
NCT06717074 ACTIVE_NOT_RECRUITING PHASE2
Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
NCT01058018 COMPLETED PHASE2
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
NCT00312052 COMPLETED PHASE2
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
NCT01226602 COMPLETED PHASE1